TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Cancer Immunotherapies Market Research Report 2022

Global Cancer Immunotherapies Market Research Report 2022

  • Category:Life Sciences
  • Published on : 16 October 2022
  • Pages :97
  • Formats:
  • Report Code:SMR-7443945
OfferClick for best price

Best Price: $2320

Cancer Immunotherapies Market Size, Share 2022


Market Analysis and Insights: Global Cancer Immunotherapies Market

The global Cancer Immunotherapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Immunotherapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Immunotherapies market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Immunotherapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Immunotherapies market.

Global Cancer Immunotherapies Scope and Market Size

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Monoclonal Antibodies (MABs)

Cancer Vaccines

Immunomodulators

Adoptive Cell transfer

Checkpoint Inhibitors

Segment by Application

Breast Cancer

Leukemia

Lymphoma

Melanoma

Colorectal Cancer

Non-Small Cell Lung Cancer

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Amgen

AstraZeneca

Roche

Bristol-Myers Squibb

Bayer

Merck

ARMO BioSciences (Eli Lilly)

Novartis

Pfizer

Johnson & Johnson

AbbVie

Gilead Sciences

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Cancer Immunotherapies product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Cancer Immunotherapies, with price, sales, revenue, and global market share of Cancer Immunotherapies from 2019 to 2022.

Chapter 3, the Cancer Immunotherapies competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cancer Immunotherapies breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Cancer Immunotherapies market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Immunotherapies.

Chapter 13, 14, and 15, to describe Cancer Immunotherapies sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Cancer Immunotherapies Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Cancer Immunotherapies Market Research Report 2022
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 97 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Cancer Immunotherapies Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapies
1.2 Cancer Immunotherapies Segment by Type
1.2.1 Global Cancer Immunotherapies Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Cancer Immunotherapies Segment by Application
1.3.1 Global Cancer Immunotherapies Sales Comparison by Application: (2022-2028)
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Global Cancer Immunotherapies Market Size Estimates and Forecasts
1.4.1 Global Cancer Immunotherapies Revenue 2017-2028
1.4.2 Global Cancer Immunotherapies Sales 2017-2028
1.4.3 Cancer Immunotherapies Market Size by Region: 2017 Versus 2021 Versus 2028
2 Cancer Immunotherapies Market Competition by Manufacturers
2.1 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2017-2022)
2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Cancer Immunotherapies Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Cancer Immunotherapies Manufacturing Sites, Area Served, Product Type
2.5 Cancer Immunotherapies Market Competitive Situation and Trends
2.5.1 Cancer Immunotherapies Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Cancer Immunotherapies Players Market Share by Revenue
2.5.3 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Immunotherapies Retrospective Market Scenario by Region
3.1 Global Cancer Immunotherapies Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Cancer Immunotherapies Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Cancer Immunotherapies Market Facts & Figures by Country
3.3.1 North America Cancer Immunotherapies Sales by Country
3.3.2 North America Cancer Immunotherapies Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Cancer Immunotherapies Market Facts & Figures by Country
3.4.1 Europe Cancer Immunotherapies Sales by Country
3.4.2 Europe Cancer Immunotherapies Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Region
3.5.1 Asia Pacific Cancer Immunotherapies Sales by Region
3.5.2 Asia Pacific Cancer Immunotherapies Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Cancer Immunotherapies Market Facts & Figures by Country
3.6.1 Latin America Cancer Immunotherapies Sales by Country
3.6.2 Latin America Cancer Immunotherapies Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Country
3.7.1 Middle East and Africa Cancer Immunotherapies Sales by Country
3.7.2 Middle East and Africa Cancer Immunotherapies Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Cancer Immunotherapies Historic Market Analysis by Type
4.1 Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
4.2 Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
4.3 Global Cancer Immunotherapies Price by Type (2017-2022)
5 Global Cancer Immunotherapies Historic Market Analysis by Application
5.1 Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
5.2 Global Cancer Immunotherapies Revenue Market Share by Application (2017-2022)
5.3 Global Cancer Immunotherapies Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Amgen Cancer Immunotherapies Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AstraZeneca Cancer Immunotherapies Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Roche Cancer Immunotherapies Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Corporation Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Bayer Cancer Immunotherapies Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Merck Cancer Immunotherapies Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 ARMO BioSciences (Eli Lilly)
6.6.1 ARMO BioSciences (Eli Lilly) Corporation Information
6.6.2 ARMO BioSciences (Eli Lilly) Description and Business Overview
6.6.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
6.7.5 ARMO BioSciences (Eli Lilly) Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Novartis Cancer Immunotherapies Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Pfizer Cancer Immunotherapies Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Corporation Information
6.11.2 AbbVie Cancer Immunotherapies Description and Business Overview
6.11.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AbbVie Cancer Immunotherapies Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Gilead Sciences
6.12.1 Gilead Sciences Corporation Information
6.12.2 Gilead Sciences Cancer Immunotherapies Description and Business Overview
6.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
6.12.5 Gilead Sciences Recent Developments/Updates
7 Cancer Immunotherapies Manufacturing Cost Analysis
7.1 Cancer Immunotherapies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Cancer Immunotherapies
7.4 Cancer Immunotherapies Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Cancer Immunotherapies Distributors List
8.3 Cancer Immunotherapies Customers
9 Cancer Immunotherapies Market Dynamics
9.1 Cancer Immunotherapies Industry Trends
9.2 Cancer Immunotherapies Market Drivers
9.3 Cancer Immunotherapies Market Challenges
9.4 Cancer Immunotherapies Market Restraints
10 Global Market Forecast
10.1 Cancer Immunotherapies Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Cancer Immunotherapies by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Cancer Immunotherapies by Type (2023-2028)
10.2 Cancer Immunotherapies Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Cancer Immunotherapies by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Cancer Immunotherapies by Application (2023-2028)
10.3 Cancer Immunotherapies Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Cancer Immunotherapies by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Cancer Immunotherapies by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Cancer Immunotherapies Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Cancer Immunotherapies Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Cancer Immunotherapies Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Cancer Immunotherapies Market Competitive Situation by Manufacturers in 2021
Table 5. Global Cancer Immunotherapies Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Cancer Immunotherapies Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Cancer Immunotherapies Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Cancer Immunotherapies Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Cancer Immunotherapies Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Cancer Immunotherapies Manufacturing Sites and Area Served
Table 11. Manufacturers Cancer Immunotherapies Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Immunotherapies as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
Table 16. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Table 17. Global Cancer Immunotherapies Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
Table 19. North America Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 20. North America Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 21. North America Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 23. Europe Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 24. Europe Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 25. Europe Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Cancer Immunotherapies Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
Table 31. Latin America Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 33. Latin America Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Cancer Immunotherapies Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 39. Global Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 40. Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 41. Global Cancer Immunotherapies Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Cancer Immunotherapies Revenue Share by Type (2017-2022)
Table 43. Global Cancer Immunotherapies Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Cancer Immunotherapies Sales (K Units) by Application (2017-2022)
Table 45. Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 46. Global Cancer Immunotherapies Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Cancer Immunotherapies Revenue Share by Application (2017-2022)
Table 48. Global Cancer Immunotherapies Price by Application (2017-2022) & (USD/Unit)
Table 49. Amgen Corporation Information
Table 50. Amgen Description and Business Overview
Table 51. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Amgen Cancer Immunotherapies Product
Table 53. Amgen Recent Developments/Updates
Table 54. AstraZeneca Corporation Information
Table 55. AstraZeneca Description and Business Overview
Table 56. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. AstraZeneca Cancer Immunotherapies Product
Table 58. AstraZeneca Recent Developments/Updates
Table 59. Roche Corporation Information
Table 60. Roche Description and Business Overview
Table 61. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. Roche Cancer Immunotherapies Product
Table 63. Roche Recent Developments/Updates
Table 64. Bristol-Myers Squibb Corporation Information
Table 65. Bristol-Myers Squibb Description and Business Overview
Table 66. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Bristol-Myers Squibb Cancer Immunotherapies Product
Table 68. Bristol-Myers Squibb Recent Developments/Updates
Table 69. Bayer Corporation Information
Table 70. Bayer Description and Business Overview
Table 71. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. Bayer Cancer Immunotherapies Product
Table 73. Bayer Recent Developments/Updates
Table 74. Merck Corporation Information
Table 75. Merck Description and Business Overview
Table 76. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Merck Cancer Immunotherapies Product
Table 78. Merck Recent Developments/Updates
Table 79. ARMO BioSciences (Eli Lilly) Corporation Information
Table 80. ARMO BioSciences (Eli Lilly) Description and Business Overview
Table 81. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product
Table 83. ARMO BioSciences (Eli Lilly) Recent Developments/Updates
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Business Overview
Table 86. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Novartis Cancer Immunotherapies Product
Table 88. Novartis Recent Developments/Updates
Table 89. Pfizer Corporation Information
Table 90. Pfizer Description and Business Overview
Table 91. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Pfizer Cancer Immunotherapies Product
Table 93. Pfizer Recent Developments/Updates
Table 94. Johnson & Johnson Corporation Information
Table 95. Johnson & Johnson Description and Business Overview
Table 96. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Johnson & Johnson Cancer Immunotherapies Product
Table 98. Johnson & Johnson Recent Developments/Updates
Table 99. AbbVie Corporation Information
Table 100. AbbVie Description and Business Overview
Table 101. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. AbbVie Cancer Immunotherapies Product
Table 103. AbbVie Recent Developments/Updates
Table 104. Gilead Sciences Corporation Information
Table 105. Gilead Sciences Description and Business Overview
Table 106. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Gilead Sciences Cancer Immunotherapies Product
Table 108. Gilead Sciences Recent Developments/Updates
Table 109. Production Base and Market Concentration Rate of Raw Material
Table 110. Key Suppliers of Raw Materials
Table 111. Cancer Immunotherapies Distributors List
Table 112. Cancer Immunotherapies Customers List
Table 113. Cancer Immunotherapies Market Trends
Table 114. Cancer Immunotherapies Market Drivers
Table 115. Cancer Immunotherapies Market Challenges
Table 116. Cancer Immunotherapies Market Restraints
Table 117. Global Cancer Immunotherapies Sales Forecast by Type (2023-2028) & (K Units)
Table 118. Global Cancer Immunotherapies Sales Market Share Forecast by Type (2023-2028)
Table 119. Global Cancer Immunotherapies Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 120. Global Cancer Immunotherapies Revenue Market Share Forecast by Type (2023-2028)
Table 121. Global Cancer Immunotherapies Sales Forecast by Application (2023-2028) & (K Units)
Table 122. Global Cancer Immunotherapies Sales Market Share Forecast by Application (2023-2028)
Table 123. Global Cancer Immunotherapies Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 124. Global Cancer Immunotherapies Revenue Market Share Forecast by Application (2023-2028)
Table 125. Global Cancer Immunotherapies Sales Forecast by Region (2023-2028) & (K Units)
Table 126. Global Cancer Immunotherapies Sales Market Share Forecast by Region (2023-2028)
Table 127. Global Cancer Immunotherapies Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 128. Global Cancer Immunotherapies Revenue Market Share Forecast by Region (2023-2028)
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Immunotherapies
Figure 2. Global Cancer Immunotherapies Market Share by Type in 2021 & 2028
Figure 3. Monoclonal Antibodies (MABs) Product Picture
Figure 4. Cancer Vaccines Product Picture
Figure 5. Immunomodulators Product Picture
Figure 6. Adoptive Cell transfer Product Picture
Figure 7. Checkpoint Inhibitors Product Picture
Figure 8. Global Cancer Immunotherapies Market Share by Application in 2021 & 2028
Figure 9. Breast Cancer
Figure 10. Leukemia
Figure 11. Lymphoma
Figure 12. Melanoma
Figure 13. Colorectal Cancer
Figure 14. Non-Small Cell Lung Cancer
Figure 15. Global Cancer Immunotherapies Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Cancer Immunotherapies Market Size (2017-2028) & (US$ Million)
Figure 17. Global Cancer Immunotherapies Sales (2017-2028) & (K Units)
Figure 18. Cancer Immunotherapies Sales Share by Manufacturers in 2021
Figure 19. Global Cancer Immunotherapies Revenue Share by Manufacturers in 2021
Figure 20. The Global 5 and 10 Largest Cancer Immunotherapies Players: Market Share by Revenue in 2021
Figure 21. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 22. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Figure 23. Global Cancer Immunotherapies Sales Market Share by Region in 2021
Figure 24. Global Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
Figure 25. Global Cancer Immunotherapies Revenue Market Share by Region in 2021
Figure 26. U.S. Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Canada Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Germany Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. France Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. U.K. Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Italy Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Russia Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Japan Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. South Korea Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. India Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Australia Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Taiwan Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Indonesia Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Thailand Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Malaysia Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Philippines Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Vietnam Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Mexico Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Brazil Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Argentina Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Turkey Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. Saudi Arabia Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 49. U.A.E Cancer Immunotherapies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 50. Sales Market Share of Cancer Immunotherapies by Type (2017-2022)
Figure 51. Manufacturing Cost Structure of Cancer Immunotherapies
Figure 52. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 53. Cancer Immunotherapies Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount